Abstract 1552P
Background
Gastric cancer is heterogenous with poor prognosis. The LEGACy project aimed to deepen GC molecular understanding through multi-omics analysis of tumours from EU and LatAm. We present partial results including histopathology, immunohistochemistry (IHC) + in-situ hybridization (ISH) markers, immune cell infiltration pattern, broad multi-gene sequencing panel and targeted transcriptomics of stage IV GC paraffin-embedded tissues.
Methods
After the central pathological confirmation of GC, standard IHC/ISH was performed, nucleic acids were extracted for DNA sequencing of 435 genes (covering mutations, copy number, fusions, MSI + TMB), and mRNA was profiled with custom Nanostring gene expression assay. The primary aim was to explore a clinically feasible diagnostic classification of GC: a. MSI; b. EBV+; c. HER2+; d. other intestinal-type (IT); and e. other poorly cohesive-type (PCT) f. and mixed. Only significant associations (P values <0.05) in non-parametric tests adjusted for multiple testing are reported.
Results
Out of 334 GC patients were enrolled in the project, 148 were eligible for molecular analysis Prevalence of GC subtypes: MSI 11%, EBV+ 4%; HER2+ 9%, IT 41%, PCT 31% and mixed 4%. We found higher HER2+ and IT tumors in EU vs. LatAm (14% vs. 6% and 46% vs. 30%, respectively). MSI tumors had highest TMB (median 38 mut/Mb) enriched for KMT2D, KRAS, PIK3CA and RNF43 mut, but no differences in immune cell infiltration/activation. EBV+ tumors had intermediate TMB (median 14 mut/Mb), highest PIK3CA mut, highest CD3/CD8 infiltration, cytotoxic and apoptotic signatures. HER2+ tumors were enriched for TP53 mut. While both IT and PCT samples had low TMB (median < 7 mut/Mb) and higher dendritic cell/mast cell infiltration, IT tumors had high cell cycle activation + TP53 mut, and PCT tumors had low Ki67, highest Hedgehog + Notch + Wnt activation scores. Interestingly, PCT tumors from LatAm had higher median TMB (7 mut/Mb) when compared to EU (4 mut/Mb). Overall, PDL1 expression was similar across the groups.
Conclusions
Our pathological-molecular classification of GC is comparable with TCGA and others, with potential differences in prevalence and mutational signatures for EU and LatAm populations that will be further explored.
Clinical trial identification
NCT04015466.
Editorial acknowledgement
Legal entity responsible for the study
INCLIVA Biomedical Research Institute, Valencia, Spain.
Funding
This work was funded by the European Union’s Horizon 2020 research and innovation program (Grant agreement No GA825832).
Disclosure
T.C. Fleitas: Financial Interests, Personal, Invited Speaker, Update on the ongoing treatment strategies for GEA: Servier; Financial Interests, Personal, Invited Speaker, The clinical impact of NRTK strategies in GI tumors: Bayer; Financial Interests, Personal, Invited Speaker, Invited as a speaker in an educational session: Bristol Myers Squibb, Amgen; Financial Interests, Personal, Invited Speaker, Invited speaker in an educational session: Bristol Myers Squibb, MSD, Lilly, Roche; Non-Financial Interests, Principal Investigator, PI of SURPASS-2 study: Adapt Immune; Non-Financial Interests, Principal Investigator, PI of a clinical trial in GEA tumors: Daiichi Sanyo; Non-Financial Interests, Principal Investigator, PI of a clinical trial: BeiGene. M. Alsina Maqueda: Financial Interests, Personal, Advisory Board: MSD, BMS, Lilly, Servier, AstraZeneca; Non-Financial Interests, Principal Investigator, Investigator Initiated trial: Merck. E. Ruiz: Financial Interests, Personal, Advisory Board: Roche, Amgen, BMS, BAYER; Financial Interests, Personal, Invited Speaker: Roche, Merck; Financial Interests, Institutional, Invited Speaker, gastric cancer talk: Astellas. F. Esteso: Financial Interests, Personal, Invited Speaker: BMS, Roche, Bayer, Amgen, Merck, Pfizer, Nutricia Bago, Raffo, Biotoscana, Servier; Financial Interests, Personal, Advisory Board: Varifarma; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Coordinating PI: Daiichi Sankyo, Roche, Mirati. S. Derks: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Invited Speaker: BMS, Servier; Financial Interests, Institutional, Funding, sponsoring investigator initiated study: Incyte. R. Dienstmann: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen, Libbs, Lilly, Merck Sharp & Dohme, Roche, Sanofi, Servier, GSK, Takeda, Janssen, Foundation Medicine; Financial Interests, Personal, Advisory Board: Bayer, Roche; Financial Interests, Personal, Full or part-time Employment, Oncoclínicas is a private healthcare provider in Brazil. I work part time as Medical Director of the Precision Medicine and Big Data Initiative. We develop molecular tests (pathology and genomics) that are offered to patients treated in the organisation as part of support programs sponsored by pharmaceutical companies and I coordinate research activities with real-world clinic-genomics cohorts.: Oncoclínicas; Financial Interests, Personal, Stocks/Shares: Trialing; Financial Interests, Personal, Research Grant: Merck. A. Cervantes: Financial Interests, Institutional, Advisory Board: Merck, Amgen, Roche, Transgene, AnHeart Therapeutics, AbbVie, GSK; Financial Interests, Institutional, Invited Speaker: Amgen, Roche, Merck, Foundation Medicine; Financial Interests, Personal, Other, Associate Editor: Annals of Oncology, ESMO Open; Financial Interests, Personal, Other, Editor in Chief: Cancer Treatment Reviews; Financial Interests, Institutional, Research Grant, Principal Investigator: Actuate Therapeutic, Amgen, Astellas Pharma, BeiGene, Bayer, AstraZeneca, BMS, Amcure, FibroGen, Lilly, Genentech, MedImmune, Merck, Novartis, Natera, MSD, Servier, Sierra Oncology, Adaptimmune, Takeda, Affimed, Roche, Seamless, Gilead, Janssen, F. STAR Therapeutics, Ribon Therapeutics; Non-Financial Interests, Other, Scientific Director: INCLIVA Biomedical Research Institute. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21